ZA974147B - Somatostatin agonists and antagonists. - Google Patents

Somatostatin agonists and antagonists.

Info

Publication number
ZA974147B
ZA974147B ZA9704147A ZA974147A ZA974147B ZA 974147 B ZA974147 B ZA 974147B ZA 9704147 A ZA9704147 A ZA 9704147A ZA 974147 A ZA974147 A ZA 974147A ZA 974147 B ZA974147 B ZA 974147B
Authority
ZA
South Africa
Prior art keywords
antagonists
somatostatin agonists
somatostatin
agonists
Prior art date
Application number
ZA9704147A
Inventor
Ankersen Michael
Stidsen Carsten Enggaard
Andersen Henrik Sune
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of ZA974147B publication Critical patent/ZA974147B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
ZA9704147A 1996-05-14 1997-05-14 Somatostatin agonists and antagonists. ZA974147B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK57696 1996-05-14

Publications (1)

Publication Number Publication Date
ZA974147B true ZA974147B (en) 1997-11-14

Family

ID=8095123

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9704147A ZA974147B (en) 1996-05-14 1997-05-14 Somatostatin agonists and antagonists.

Country Status (5)

Country Link
EP (1) EP0912551A1 (en)
JP (1) JP2001525793A (en)
AU (1) AU2764797A (en)
WO (1) WO1997043278A1 (en)
ZA (1) ZA974147B (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127343A (en) * 1996-05-14 2000-10-03 Novo Nordisk A/S Somatostatin agonists and antagonists
US6159941A (en) * 1996-05-14 2000-12-12 Novo Nordisk A/S Use of somatostatin agonists and antagonists for treating diseases related to the eye
US6057338A (en) * 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
US6063796A (en) * 1997-04-04 2000-05-16 Merck & Co., Inc. Somatostatin agonists
US6025372A (en) * 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
ES2174447T3 (en) * 1997-06-24 2002-11-01 Novo Nordisk As USE OF SOMATOSTATIN AGONISTS AND ANTAGONISTS FOR THE TREATMENT OF EYE DISEASES.
US6124256A (en) * 1998-03-27 2000-09-26 Haeyry; Pekka Method for the prevention of a patient's fibroproliferative vasculopathy
CZ20004568A3 (en) * 1998-06-12 2001-11-14 Societe De Conseils De Recherches Et D'application Imidazolyl compound, pharmaceutical preparation and preparation process thereof
CA2246791A1 (en) * 1998-09-01 2000-03-01 Alison Buchan Treatment of endothelium with somatostatin analogues
WO2000023420A1 (en) * 1998-10-20 2000-04-27 Takeda Chemical Industries, Ltd. Aromatic amine derivatives, process for the preparation thereof and agents containing the same
US6387932B1 (en) 1999-06-25 2002-05-14 Merck & Co., Inc. Somatostatin agonists
FR2796945B1 (en) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic NOVEL DERIVATIVES OF HYDANTOINS, THIOHYDANTOINS, PYRIMIDINEDIONES AND THIOXOPYRIMIDINONES, PROCESSES FOR THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
ES2333097T3 (en) 2000-05-31 2010-02-17 Raqualia Pharma Inc USE OF SECRETAGOGS OF GROWTH HORMONE TO STIMULATE GASTROINTESTINAL MOTILITY.
AR035040A1 (en) 2000-08-01 2004-04-14 Sod Conseils Rech Applic IMIDAZOLIL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF THEM FOR THE PREPARATION OF MEDICINES ABLE TO SELECTIVELY JOIN SUBTIPOS OF THE SOMATOSTATIN RECEIVER
SE0202134D0 (en) * 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
DE60329030D1 (en) * 2002-12-04 2009-10-08 Ore Pharmaceuticals Inc Melanocortin receptor MODULATORS
US7371871B2 (en) 2003-05-05 2008-05-13 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8338120B2 (en) 2003-05-05 2012-12-25 Probiodrug Ag Method of treating inflammation with glutaminyl cyclase inhibitors
US7381537B2 (en) 2003-05-05 2008-06-03 Probiodrug Ag Use of inhibitors of glutaminyl cyclases for treatment and prevention of disease
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
FI20031454A0 (en) 2003-10-06 2003-10-06 Juvantia Pharma Ltd Oy Selective somatostatin receptor 1 and / or 4 agonists and antagonists
JP5707014B2 (en) 2003-10-15 2015-04-22 プロビオドルグ エージー Use of glutaminyl and glutamate cyclase effectors
EA013790B1 (en) * 2004-02-05 2010-06-30 Пробиодруг Аг Novel inhibitors of glutaminyl cyclase
CN1918131B (en) * 2004-02-05 2011-05-04 前体生物药物股份公司 Novel inhibitors of glutaminyl cyclase
WO2005082844A1 (en) * 2004-02-27 2005-09-09 Oy Juvantia Pharma Ltd Treatment of diseases by using a somatostatin receptor agonist
WO2005082845A1 (en) * 2004-02-27 2005-09-09 Oy Juvantia Pharma Ltd Novel therapies with somatostatin receptor agonists
CU23558A1 (en) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE
CN101657436A (en) 2007-02-09 2010-02-24 特兰齐姆制药公司 Macrocyclic ghrelin receptor modulators and using method thereof
EP2117540A1 (en) * 2007-03-01 2009-11-18 Probiodrug AG New use of glutaminyl cyclase inhibitors
CN105764887A (en) 2013-09-12 2016-07-13 住友化学株式会社 Nitrogen-containing saturated heterocyclic compound
JP7099717B2 (en) 2019-09-30 2022-07-12 株式会社理研バイオ Somatostatin receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3579000D1 (en) * 1985-04-02 1990-09-06 Heumann Pharma Gmbh & Co IMIDAZOLYLALKYLGUANIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS.
NL8601585A (en) * 1986-06-19 1988-01-18 Vereniging Voor Christelijk Wetenschappelijk Onderwijs N- (2-SUBSTITUTED ALKYL) -N-IMIDAZOL-4-YL ALKYL GUANIDINE.
DE3631334A1 (en) * 1986-09-15 1988-03-17 Heumann Pharma Gmbh & Co NEW IMIDAZOLYLGUANIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
ES2058651T3 (en) * 1990-03-30 1994-11-01 Heumann Pharma Gmbh & Co USE OF GUANIDINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICINE WITH ANTAGONIST ACTIVITY OF NPY.

Also Published As

Publication number Publication date
AU2764797A (en) 1997-12-05
WO1997043278A1 (en) 1997-11-20
JP2001525793A (en) 2001-12-11
EP0912551A1 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
ZA974147B (en) Somatostatin agonists and antagonists.
ZA979701B (en) Constrained somatostatin agonists and antagonists.Constrained somatostatin agonists and antagonists.
EP1023061A4 (en) Somatostatin agonists
EP0977751A4 (en) Somatostatin agonists
EP0984779A4 (en) Somatostatin agonists
IL133377A0 (en) Glucagon antagonists/inverse agonists
IL139136A0 (en) Il-2 selective agonists and antagonists
ZA972570B (en) Cement additives.
AU1285499A (en) Somatostatin agonists
EP0934305A4 (en) Integrin antagonists
ZA973891B (en) Microparticles.
AU1772300A (en) Glucagon antagonists/inverse agonists
ZA972375B (en) 2-aryl-substituted pyridines.
EP0946164A4 (en) Integrin antagonists
IL130660A0 (en) Benzothiophenecarboxamide derivatives and PGD2 antagonists comprising them
ZA200100978B (en) Muscarinic agonists and antagonists.
ZA9711456B (en) VEGF-B/receptor complex and uses thereof.
ZA971184B (en) Endothelin antagonists.
GB9701374D0 (en) Purinergic agonists and antagonists
ZA9711047B (en) Formulation and use.
GB9613592D0 (en) Bore probe
AU3935897A (en) B1-bradykinin receptor antagonists and use thereof
PL307138A1 (en) Amyline antagonists and agonists
GB9625686D0 (en) Tapered speeddeck
ZA9710855B (en) Somatostatin antagonists.